Dmydb.St

DMYDB.ST has a highly liquid capital structure, with cash and equivalents amounting to 277.19 million SEK, significantly exceeding its total liabilities of 72.64 million SEK. The company's liquidity position is further reinforced by a current ratio of 10.64, indicating a strong ability to meet short-term obligations. However, the company is operating at a loss, with a net income of -169.78 million SEK and an operating income of -183.74 million SEK, which suggests a lack of profitability.

The company's return on equity (ROE) is -60.63%, and its return on assets (ROA) is -48.14%, both of which are significantly below the industry norms for profitable biotechnology firms. These metrics indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The debt-to-equity ratio of 0.16 suggests a conservative capital structure, with minimal reliance on debt financing.

There is no detailed breakdown of revenue by segments or geographic regions provided in the available data. However, the company's revenue for the period under review is reported at 130.00 million SEK, which is relatively modest for a biotechnology firm. The absence of segment-specific data limits the ability to assess the company's diversification and exposure to different markets.

The company's growth trajectory appears to be constrained, with no clear indication of revenue growth in the near term. Analyst estimates suggest a mean revenue of 0.00 SEK, which implies a lack of consensus on the company's ability to generate revenue in the future. The company's operating cash flow is negative at -169.68 million SEK, and its free cash flow is also negative at -173.32 million SEK, indicating that the company is not generating sufficient cash from operations to sustain its activities.

The risk assessment for DMYDB.ST indicates a low level of liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags, suggesting that the company is not currently facing significant financial distress or the need for equity dilution. The company's capital expenditure of -10.05 million SEK indicates that it is not investing heavily in new projects or infrastructure, which may limit its long-term growth potential.

Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The lack of detailed information makes it challenging to assess the company's recent performance and future prospects. The company's mean EPS estimate is -1.08 SEK, and its mean EBIT estimate is -158.00 million SEK, both of which indicate a lack of profitability and operational efficiency.